Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 6, 2017

View Archived Issues

AVROBIO licenses cystinosis program from Genstem Therapeutics

CD36 is a promising drug target for treating T2DM

Board recommends continuing Athenex's phase III Oraxol 001 study

Sirtuin-6 could be modulated to prevent NASH progression

FDA gives orphan drug status to CytoDyn's PRO-140

PCI Biotech's fimaporfin wins orphan drug status in U.S.

Kyowa Hakko Kirin doses first patient in phase II trial of entinostat

Aerie Pharmaceuticals acquires rights to PRINT technology in ophthalmology

Monoclonal antibodies developed to target both dengue and Zika viruses

FDA accepts Methylene Blue MMX NDA

Immatics closes USD 58 million series E financing

EMA accepts Cinfa's MAA for biosimilar pegfilgrastim B-12019

Emory University patents antiviral compounds for hepatitis B, hepatitis C and West Nile viruses

The University of California, Oakland presents novel apoptosis inducers and splicing modulators

STAT3-targeting antibody SBT-100 given U.S. orphan drug designation

GlaxoSmithKline identifies novel integrin alphavbeta6 receptor antagonists

Novel oligopeptides created at Guangzhou Nuowei Biotechnology

AstraZeneca identifies new serine-protein kinase ATM inhibitors

FDA approves cobas Zika test to screen blood donations

Zealand establishes research collaboration with Torrey Pines Institute for Molecular Studies

Acadia Pharmaceuticals starts phase III HARMONY trial of Nuplazid

KemPharm and Genco sign licensing agreement to develop prodrug for pediatric Tourette's with ADHD

Phase III TIVO-3 trial of Fotivda to continue as planned following futility analysis

Role of CD36 in islet dysfunction makes it a target for treating diabetes

AOBiome begins enrollment in phase Ib/IIa of AOB product for SAR

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 6, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for May 5, 2026
Cytospire raises £61M series A to target EGFR in solid tumors
BioWorld
Next-generation T-cell engager (TCE) specialist Cytospire Therapeutics Ltd. has raised £61 million (US$82.7 million) in a series A round, equipping it to advance...
Bio Korea 2026: US policy risks shift to execution framework
BioWorld
Regulatory uncertainty that dominated the life science sector in 2025 is transitioning into an execution framework for biotechnology companies, provided companies...
Latus Bio series A financing supports early-stage programs
BioWorld Science
Latus Bio Inc. has closed a $97 million series A financing to support its broad therapeutics pipeline based on novel AAV capsid variants. Proceeds from the...